Quanterix (Quanterix) Risk Assessment

View and export this data going back to 2017. Start your Free Trial

What is Quanterix Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Quanterix is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Quanterix's Risk Assessment

For the Medical Devices subindustry, Quanterix's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quanterix's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Quanterix's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Quanterix's Risk Assessment falls into.

Quanterix (NAS:QTRX) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Quanterix Risk Assessment Related Terms

Thank you for viewing the detailed overview of Quanterix's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Quanterix (Quanterix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quanterix Corp (NAS:QTRX) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 Middlesex Turnpike, Billerica, MA, USA, 01821

Website

https://www.quanterix.com

Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum and other fluids which are undetectable using conventional, analog immunoassay technologies. The company has developed Simoa technology which is a method of detection of proteins and has the capability of analyzing nearly six biomarkers per test, with anticipated expansion capability.

Executives

Laurie J Olson	director	C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
William P Donnelly	director	C/O INGERSOLL RAND INC., 525 HARBOUR PLACE DRIVE, SUITE 600, DAVIDSON NC 28036
Vandana Sriram	officer: Chief Financial Officer	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Brian J Blaser	director	561 CIRCLE LANE, LAKE FOREST IL 60045
Michael A Doyle	officer: CFO and Treasurer	C/O EASYLINK SERVICES CORPORATION, 33 KNIGHTSBRIDGE ROAD, PISCATAWAY NJ 08854
Masoud Toloue	officer: President, Quanterix & Dx	C/O QUANTERIX CORP, 900 MIDDLESEX TURNPIKE, BILLERICA MA 01821
Sarah E. Hlavinka	director	2111 N MOLTER RD, LIBERTY LAKE WA 99019
Paul M Meister	director	18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862
David R Walt	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Martin D Madaus	director	290 CONCORD ROAD, BILLERICA MA 01821
John J Fry	officer: General Counsel & Secretary	8 CENTENNIAL DRIVE, PEABODY MA 01960
E Kevin Hrusovsky	director, officer: EC, President & CEO	68 ELM STREET, HOPKINTON MA 01748
Karen Flynn	director	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
David C. Duffy	officer: SVP R&D and CTO	C/O QUANTERIX CORPORATION, 113 HARTWELL AVENUELE, LEXINGTON MA 02421
Dawn Mattoon	officer: Sr VP, Stgc Mrktg & Assay Tech	113 HARTWELL AVENUE, C/O QUANTERIX CORPORATION, LEXINGTON MA 02421